We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Panel of Urinary Peptides Used to Diagnose Liver Fibrosis

By LabMedica International staff writers
Posted on 24 Nov 2020
Print article
Image: Micrograph showing fibrosis of the liver caused by cirrhosis. The tissue in this example is stained with a trichrome stain, in which fibrosis is colored blue. The red areas are the nodular liver tissue (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing fibrosis of the liver caused by cirrhosis. The tissue in this example is stained with a trichrome stain, in which fibrosis is colored blue. The red areas are the nodular liver tissue (Photo courtesy of Wikimedia Commons)
A panel of 50 urinary peptides was shown to be a useful tool for the early diagnosis of liver fibrosis.

Liver fibrosis may result from infection by viruses such as hepatitis B and C, excessive alcohol consumption, a build-up of fat in the liver, or some autoimmune diseases. When the liver becomes fibrotic, accumulation of proteins causes the organ to shrink and become stiffer, which impedes its function. Peptide fragments of these proteins enter the bloodstream, where they are channeled into the kidneys and removed from the body via the urine.

Investigators at the University of Warwick (United Kingdom) and their colleagues sought to determine if these excreted peptides could be used to diagnose liver fibrosis in patients with chronic liver disease.

For this study, the investigators recruited 129 patients with varying degrees of liver fibrosis and 223 controls without liver fibrosis. Additionally, 41 patients with no liver, but kidney fibrosis were included to evaluate interference with expressions of kidney fibrosis. Urinary low molecular weight peptides were analyzed by capillary electrophoresis coupled to mass spectrometry.

Capillary electrophoresis coupled to mass spectrometry (CE-MS) has emerged in recent years as a hybrid technology using capillary electrophoresis (CE) instead of liquid chromatography for sensitive and high-resolution low molecular weight protein and peptide separation before mass spectrometry (MS). Notably, this method enables profiling urinary peptides in a mass range of 0.8 to 20 kilodalton (kDa).

Results revealed that CE-MS enabled identification of 50 urinary peptides associated with liver fibrosis. The peptides were sequenced and shown to be mainly fragments of collagen chains, uromodulin, and Na/K-transporting ATPase subunit gamma.

The investigators used this panel of 50 peptides to evaluate urine samples from a new group of patients. They reported correct identification of liver fibrosis patients in 84.2% of cases (sensitivity), and correct identification of those without fibrosis in 82.4% of cases (specificity).

Senior author Dr. Ramesh Arasaradnam, associate professor of gastroenterology at the University of Warwick Medical School, said, "Analyzing urine for the purposes of diagnostics is a promising research area, and this new study builds on existing work in my research group looking at urine peptides in colon cancer. While we are unlikely to see this in clinical practice for some time, it provides an avenue for further investigation that could help in the prevention of this terrible condition."

The liver fibrosis study was published in the November 5, 2020, online edition of the journal EbioMedicine.

Related Links:
University of Warwick


Print article

Channels

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Image: BioProfile FLEX2 Cell Culture Analyzer (Photo courtesy of Nova Biomedical)

Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer

Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.